Balyasny Asset Management L.P. and related reporting persons filed Amendment No. 3 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,120,982 shares of Opus Genetics Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Each of the five reporting persons is listed as beneficially owning 6,120,982 shares of Opus Genetics Inc. common stock.
- Percent of class: The 6,120,982 shares represent approximately 7.36% of outstanding shares, based on 83,195,823 shares outstanding as of August 3, 2026.
- Share composition: The reported amount consists of 3,728,638 shares and 2,392,344 shares issuable upon exercise of 2,392,344 warrants, subject to a Beneficial Ownership Limitation.
- Beneficial Ownership Limitation: The warrants include a blocker preventing exercise to the extent the holder would beneficially own more than 9.99% of outstanding shares as a result of such exercise.
- Direct holder: According to the filing, Atlas Diversified Master Fund, Ltd. ("ADMF"), a Cayman Islands exempted company, is the direct holder of the shares.
- Sole voting and dispositive power: Each reporting person is listed with sole voting power and sole dispositive power over all 6,120,982 shares, with zero shared voting or dispositive power.
Balyasny Entity Structure and Opus Genetics Stake Details
The Schedule 13G Amendment No. 3 names five reporting persons: Balyasny Asset Management L.P. ("BAM"), BAM GP LLC ("BAM GP"), Balyasny Asset Management Holdings LP ("BAM Holdings"), Dames GP LLC ("Dames"), and Dmitry Balyasny, a United States citizen. According to the filing, BAM GP is the General Partner of BAM, BAM Holdings is the Sole Member of BAM GP, Dames is the General Partner of BAM Holdings, and Dmitry Balyasny is the Managing Member of Dames. All entities are organized in Delaware, and the principal business address for each is 444 West Lake Street, 50th Floor, Chicago, IL 60606.
The filing states that BAM serves as investment manager of ADMF, the direct holder of the 6,120,982 shares reported. By virtue of their respective positions within this ownership chain, each of BAM GP, BAM Holdings, Dames, and Mr. Balyasny "may be deemed to exercise voting and investment power" over the shares held directly by ADMF, and thus each "may be deemed to beneficially own" such shares, according to the filing. The triggering event for this amendment was September 30, 2026.
The filing notes that the 7.36% figure is based on 83,195,823 shares outstanding as of August 3, 2026, as reported in Opus Genetics Inc.'s Form 10-Q filed with the SEC on August 6, 2026. The 2,392,344 warrants included in the total are subject to a blocker that prevents exercise if doing so would cause the holder's beneficial ownership to exceed 9.99% of outstanding shares.
What Was Disclosed
Balyasny Asset Management L.P. and four affiliated entities and persons filed Amendment No. 3 to Schedule 13G reporting combined beneficial ownership of 6,120,982 shares, or approximately 7.36%, of Opus Genetics Inc. common stock, with the event date of September 30, 2026.




Please wait processing your request...